Takeda Pharmaceutical Company Limited - SIC # 7339 -

Ticker Exchange SIC # Website Latest Ticker
TAK New York 7339 www.takeda.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Takeda Pharmaceutical Company Limited

What's Fueling Tempus AI's Explosive Sales Growth? - Jul 2nd, 2025 6:11 am
FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency - Jul 1st, 2025 3:30 am
Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1 - Jun 30th, 2025 6:00 am
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last? - Jun 27th, 2025 7:15 am
Will Strong Asceniv Sales Drive ADMA Biologics Further? - Jun 27th, 2025 6:11 am
Liver Organoid Breakthrough: Generating Organ-Specific Blood Vessels - Jun 25th, 2025 12:11 pm
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last? - Jun 25th, 2025 9:13 am
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today? - Jun 25th, 2025 6:54 am
Takeda Announces New Assignments of Directors - Jun 25th, 2025 1:07 am
Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera - Jun 24th, 2025 1:09 pm
ADMA Looks to Expand Asceniv's Label: Will This Boost Sales? - Jun 16th, 2025 11:06 am
EC approves Takeda ADC plus chemo for stage IIb Hodgkin’s lymphoma - Jun 4th, 2025 2:47 am
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD - Jun 3rd, 2025 8:12 am
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera - Jun 1st, 2025 6:00 am
Xoma Royalty Acquires Mezagitamab Royalty, Milestone Rights From BioInvent - May 27th, 2025 8:58 am
Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award - May 27th, 2025 5:30 am
Takeda Taps Salesforce (CRM) for AI-Driven Customer Experience Platform - May 20th, 2025 11:33 am
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1 - May 14th, 2025 3:03 pm
Top 4 GARP Stocks With Attractive PEG Ratios to Watch - May 9th, 2025 1:00 pm
Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress - May 8th, 2025 12:36 am